kidney cancer

Deal terminate tear up end deal scrap

Allarity loses rights to Novartis cancer drug over payments

Allarity has been told that Novartis is rescinding the rights to a troubled cancer drug after the biotech failed to keep up with its payments.

James Waldron Feb 2, 2024 9:09am

Merck

Merck's HIF-2α med nabbed in Peloton buyout, keeps on delivering

Sep 18, 2020 3:00am

Red blood cells

Dana-Farber researchers spot early kidney cancer with blood test

Jun 22, 2020 11:00am

opdivo

Why 'hot' kidney tumors don't respond to PD-1 blockers

May 29, 2020 11:00am

Merck

Merck backs up Peloton buyout with promising kidney cancer data

May 13, 2020 5:00pm

nephrons

Could the anti-cancer gene p53 be a target in kidney cancer?

Dec 20, 2019 9:42am